This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
The Evolution of Multiple Myeloma Patient Management: Managing Today, Preparing for Tomorrow

The Evolution of Multiple Myeloma Patient Management: Managing Today, Preparing for Tomorrow

Format

Clinical Review

Time to Complete

3 hours

Released

December 31, 2018

Expires

December 31, 2019
Add to Queue


Maximum Credits

3.00 / AMA PRA Category 1 Credit(s)TM

Accredited Provider

This CME-certified enduring activity is jointly provided by Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation.

Commercial Supporter

Support for this activity has been provided through educational grants from Adaptive Biotechnologies, Amgen, and Celgene Corporation.

Program Description

The clinical multiple myeloma arena has undergone significant advances in diagnosis and prognosis, minimal residual disease monitoring, and supportive care. This expansion brings renewed hope to patients, but it presents new challenges for the clinicians charged with their care. Some patients enjoy many years in clinical remission, whereas for others survival is no more than 2 or 3 years. This reflects the heterogeneity of myeloma and underscores the inappropriateness of a one-size-fits-all management approach. Improving patient outcomes requires building on the foundation of current therapies and ensuring that clinicians are equipped with the knowledge and strategies needed to provide patients with a more personalized approach to treatment. Oncology clinicians have a growing array of tools at their disposal to favorably influence a patient’s quality and quantity of life—but they can only take advantage of these tools by remaining current on the latest research and understanding the appropriate timing and strategies for using newer therapies.

Intended Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care providers involved in the care of patients with multiple myeloma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Incorporate the most current imaging procedures, cytogenetics, genomics, and other testing tools to define patient prognosis and risk stratification
  • Select treatment combinations in the frontline setting based on risk and patient-specific characteristics
  • Describe the advantages and limitations of measuring minimal residual disease
  • Identify patients who may benefit from consolidation and/or maintenance therapy
  • Incorporate the use of novel agent/monoclonal antibody–based regimens for relapsed/refractory patients based on currently available evidence, including patient-specific features and genomics
  • Evaluate emerging data from clinical trials on oral small-molecule inhibitors and immune-oncology–based treatment regimens

Conflict Of Interest Disclosure Policy

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Faculty

Paul G. Richardson, MD—Program Co-Chair
R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader and Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Dr. Richardson has disclosed the following relevant financial relationships:
Consultant/Advisor: Celgene, Janssen, Takeda
Research Funding: Bristol-Myers Squibb, Celgene, Oncopeptides, Takeda

A. Keith Stewart, MBChB, MRCP, FRCPC, MBA—Program Co-Chair
Carlson and Nelson Endowed Director
Center for Individualized Medicine
Vasek and Anna Maria Polak Professor of Cancer Research
Consultant, Division of Hematology/Oncology
Mayo Clinic
Scottsdale, Arizona

Dr. Stewart has disclosed the following relevant financial relationships:
Consultancy or Honoraria: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Ionis, Janssen, Ono, Seattle Genetics, Takeda
Membership on a Board or Advisory Committee: Genomics England, Helix, Veritas

Ajai Chari, MD
Associate Professor of Medicine
Director of Clinical Research, Multiple Myeloma Program
Icahn School of Medicine at Mount Sinai
New York, New York

Dr. Chari has disclosed the following relevant financial relationships:
Grant or Research Support: Amgen, Celgene, Janssen, Millennium/Takeda, Novartis Pharmaceuticals, Pharmacyclics
Paid Consultant: Amgen, Celgene, Janssen, Karyopharm, Millennium/Takeda, Novartis Pharmaceuticals, Oncopeptides, Sanofi

C. Ola Landgren, MD, PhD
Chief, Myeloma Service
Professor of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Dr. Landgren has disclosed the following relevant financial relationships:
Grant Support: NIH, FDA, MMRF, IMF, LLS, Perelman Family Foundation, Rising Tides Foundation, Amgen, Celgene, Glenmark, Janssen, Karyopharm, Seattle Genetics, Takeda
Honoraria/Ad Boards: Adaptive, Amgen, Binding Site, Bristol-Myers Squibb, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer
Chairman for “Medscape myeloma”: 2014–ongoing
Independent Data Monitoring Committee (IDMC): Janssen, Merck, Takeda,

María-Victoria Mateos, MD, PhD
Associate Professor of Hematology
Director, Myeloma Unit
University Hospital of Salamanca
Salamanca, Spain

Dr. Mateos, MD has disclosed the following relevant financial relationships:
Honoraria: Amgen, Celgene, Janssen, Takeda
Advisory Boards: AbbVie, Amgen, Celgene, GSK, Janssen, PharmaMar, Seattle Genetics, Takeda

Gregory J. Orloff, MD
Member, Multiple Myeloma Research Consortium
Virginia Cancer Specialists
Assistant Professor of Oncology
Fairfax, Virginia

Dr. Orloff has disclosed no relevant financial relationships.

Accredited Provider Disclosures

Penn State College of Medicine
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

Multiple Myeloma Research Foundation
Mary DeRome
, Director of Medical Communications and Education, has disclosed no relevant financial relationships.
Anne Quinn Young, MPH, Vice President of Development & Strategic Partnerships, has disclosed the following relevant financial relationship:
Shareholder: Bluebird

RedMedEd
Denise C. LaTemple, PhD
, Director of Scientific Services, has disclosed no relevant financial relationships.
Kristen Petro Slade, Director of Operations, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships.
Karen Smith, Creative Director, has disclosed no relevant financial relationships.
Karen Tenaglia, Project Manager, has disclosed no relevant financial relationships.

Credit

3.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Penn State College of Medicine designates this enduring activity for a maximum of 3.00 AMA PRA Category 1 Credit(s)TM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Penn State College of Medicine, RedMedEd, the Multiple Myeloma Research Foundation, Adaptive Biotechnologies, Amgen, and Celgene Corporation do not recommend the use of any agent outside the labeled indications.

Discussion of off-label drug use: Venetoclax

Disclaimer

The information presented at this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Penn State College of Medicine, RedMedEd, the Multiple Myeloma Research Foundation, Adaptive Biotechnologies, Amgen, or Celgene Corporation. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions

To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

Privacy Policy

CME credit for this activity is provided by Penn State College of Medicine. If you register for CME credit for this educational activity, RedMedEd will forward relevant personally identifiable information to Penn State College of Medicine so that records can be maintained concerning any credits issued to you. Aggregated data concerning registrations, posttests, and evaluations may be shared, but RedMedEd will not knowingly share any personally identifiable information. Penn State College of Medicine may use the information you provide on this site to contact you about your CME credit or other relevant educational activities provided through Penn State College of Medicine. For more information, contact ContinuingEd@hmc.psu.edu.

myCME privacy policy

Copyright

© 2018. This CME-certified program is held as copyrighted by Penn State College of Medicine and RedMedEd. Through this notice, Penn State College of Medicine and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue